Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP1002 in Advanced Lymphoid Malignancies
NCT04072458Phase 1Active, not recruiting
- Sponsor
- Bio-Path Holdings, Inc.
- Start
- Nov 2020
- Primary completion
- Apr 2025
- Modality
- Modified DNA Oligonucleotides, Targeted Liposomes, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BP1002 in mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and 7 more, sponsored by Bio-Path Holdings, Inc. Primary endpoints: Dose Limiting Toxicity at 30 days, Treatment-Emergent Adverse Events at 30 days and 8 more. Started Nov 2020; status: active, not recruiting.
02
Drugs
BP1002
03
Conditions
mantle cell lymphoma (MCL)peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04072458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072458.